Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ekso Bionics Holdings (EKSO) EBITDA Margin (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed EBITDA Margin for 13 consecutive years, with 148.6% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 10011.0% to 148.6% in Q4 2025 year-over-year; TTM through Dec 2025 was 104.26%, a 4552.0% decrease, with the full-year FY2025 number at 104.26%, down 4552.0% from a year prior.
  • EBITDA Margin was 148.6% for Q4 2025 at Ekso Bionics Holdings, down from 34.02% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 34.02% in Q3 2025 to a low of 185.51% in Q2 2025.
  • A 5-year average of 95.25% and a median of 83.55% in 2024 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: surged 46527bps in 2021, then plummeted -13856bps in 2025.
  • Ekso Bionics Holdings' EBITDA Margin stood at 55.66% in 2021, then plummeted by -107bps to 115.49% in 2022, then soared by 32bps to 78.21% in 2023, then surged by 38bps to 48.49% in 2024, then tumbled by -206bps to 148.6% in 2025.
  • Per Business Quant, the three most recent readings for EKSO's EBITDA Margin are 148.6% (Q4 2025), 34.02% (Q3 2025), and 185.51% (Q2 2025).